RxDoctor Payments Data

Maria Crespin

Nurse Practitioner · Las Cruces, NMNPI 1922515675

Payments from drug & device makers

$715in general payments, 2019–2025

Across 16 payments — averaging $44.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$151
  • Otsuka America Pharmaceutical, Inc.$125
  • Novo Nordisk$120
  • Neurocrine Biosciences, Inc.$119
  • Acadia Pharmaceuticals Inc$93
  • Boehringer Ingelheim$41
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$715 in reported general payments places this provider in the 80th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$10,936
Medicare patients
115
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$61,027
JardianceEmpagliflozin12$13,361
Atorvastatin Calcium62$812
Metoprolol Succinate45$769
Amlodipine Besylate55$556
Ezetimibe26$523
Carvedilol58$494
Losartan Potassium34$320
Rosuvastatin Calcium12$244
Lisinopril39$209
Metoprolol Tartrate44$181
Furosemide16$106
Spironolactone15$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$41$13,36112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →